DSP-2230
DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC50s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain[1][2][3][4].
Product Specifications
CAS Number
1233231-30-5
Product Name Alternative
ANP-230
UNSPSC
12352005
Target
Sodium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/dsp-2230.html
Concentration
10mM
Purity
98.33
Solubility
DMSO : ≥ 100 mg/mL
Smiles
C[C@H](NCC1=NC2=CC=C(OC3=CC(F)=C(F)C(F)=C3)N=C2N1C4CCC4)C(N)=O
Molecular Formula
C20H20F3N5O2
Molecular Weight
419.40
References & Citations
[1]Bagal SK, et al. Voltage gated sodium channels as drug discovery targets. Channels (Austin) . 2015;9 (6) :360-6.|[2]Sara Sabina Hadida-Ruah, et al. Sulfonamides as modulators of sodium channels.|[3]Okuda H, et al., Reduced pain sensitivity of episodic pain syndrome model mice carrying a Nav1.9 mutation by ANP-230, a novel sodium channel blocker. Heliyon. 2023 Apr 14;9 (4) :e15423.|[4]Kamei T, et al., Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230. Biochem Biophys Res Commun. 2024 Aug 20;721:150126.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Nav1.7; Nav1.8; Nav1.9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
248243-ML650 100 µL
LNX2 (Ligand of numb-Protein X 2, FLJ12933, FLJ23932, FLJ38000, MGC46315, PDZRN1) (MaxLight 650)
Sign In for Pricing
View Details I7662-16S 100 µg
Interferon gamma (IFNg) discontinued. see I7661-66Q
Sign In for Pricing
View Details